Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579287 · ClinicalTrials.gov registry record · Phase 2
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
A Phase 2 study of Myopia, Progressive, sponsored by Sunhawk Vision Biotech.
- Active
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 9
- Study locations
NCT06579287: Active Phase 2 study of Myopia, Progressive, sponsored by Sunhawk Vision Biotech.
NCT06579287 is a Phase 2 study of Myopia, Progressive that is active but no longer recruiting, run by Sunhawk Vision Biotech. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 9 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06579287, a Phase 2 study of Myopia, Progressive, is active but no longer recruiting, sponsored by Sunhawk Vision Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 9
- Study locations
Study Summary
The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
Conditions Studied
Interventions
- DRUG Atropine
- DRUG SHJ002
Study Locations (9)
Other
- Changhua Christian Hospital - Chang-hua
- Kaohsiung Veterans General Hospital - Kaohsiung City
- Chang Cung Memorial Hospital-Tucheng - New Taipei City
- MacKay Memorial Hospital-Tamsui - New Taipei City
- Chung Shan Medical University Hospital - Taichung
- Cathay General Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
- Tri-Service General Hospital - Taipei
Ohio
- Pacific Center for Advanced Vision Care Tanasbourne Vision Center - Hillsboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT06579287 still lists
NCT06579287 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Myopia, Progressive appearing as the primary indexed condition, and to 2 interventions - of which Atropine is the first listed.
NCT06579287 lists 9 locations in 2 states (Other, Ohio).
Frequently Asked Questions
What is clinical trial NCT06579287 about?
NCT06579287 is a clinical study titled "A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control". The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
What is the current status of trial NCT06579287?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-01-22. Estimated completion is 2026-12.
What conditions does trial NCT06579287 study?
This clinical trial studies the following conditions: Myopia, Progressive.
What interventions are being tested in trial NCT06579287?
The interventions under investigation include: Atropine (DRUG), SHJ002 (DRUG).
Who is sponsoring clinical trial NCT06579287?
This trial is sponsored by Sunhawk Vision Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06579287 being conducted?
This trial has 9 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia, Progressive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06579287's enrollment target sits among peer trials
140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI